# Protera Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/protera-biosciences

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.proterabio.com
- Total disclosed funding: $9.4M
- Latest round: Series A (Oct 11, 2021)
- Investors on record: 3

## About

Based in France, Protera Biosciences, Inc. specializes in developing innovative functional ingredients for the food industry through advanced protein engineering and artificial intelligence, focusing on enhancing food quality and functionality.Protera Biosciences, Inc. was founded in Paris, France in 2015, and operates with a focus on creating advanced protein solutions for the food sector. The company has completed three funding rounds, with the latest being a Series A round on 11 October 2021, raising EUR 3.587 mn from investors including Grupo Bimbo SAB de CV and Sofinnova Partners. The company's current valuation is EUR 25.940 mn, led by CEO and founder Leonardo Alvarez, who has a history of driving innovation in the food technology space.Protera specializes in the development of innovative functional ingredients for the food industry, leveraging advanced protein engineering and artificial intelligence. Their core offerings include the madi™ platform, designed to tackle complex challenges related to protein functionality, discovery, and production efficiency. Through generative AI and computational biology, Protera aims to unlock novel protein applications via precision fermentation at an industrial scale. Their products cater to a diverse client base, including food manufacturers and developers seeking to enhance product quality and functionality, primarily targeting markets in North America and Europe, where there is growing demand for sustainable and high-performance food ingredients.Protera's revenue model is structured around partnerships and collaborations with food industry stakeholders, encompassing both B2B transactions and direct-to-consumer offerings. Client interactions typically involve long-term contracts or agreements for unique protein ingredients developed through the madi™ platform. Companies may engage in subscription-based arrangements for ongoing access to Protera's products or services, ensuring a steady flow of revenue. The pricing structure reflects the advanced technology and R&D that underpins their flagship offerings, though specific pricing details remain undisclosed.Protera Biosciences, Inc. plans to utilize the EUR 3.587 mn raised in its Series A funding round in October 2021 to advance its protein platform as it moves towards commercializing its product portfolio. The company aims to expand its product offerings and enhance its capabilities within the food innovation sector. Specific future products are currently in development, with plans to enter new markets in Europe and North America by 2023, addressing the increasing demand for sustainable food solutions.

## Funding rounds

- Series A, Oct 11, 2021, $4.2M — Sofinnova Partners, Grupo Bimbo SAB de CV, SOSV
- Series A, Apr 30, 2021, $2.7M — Sofinnova Partners, SOSV
- Series A, Mar 24, 2020, $2.5M — Sofinnova Partners, SOSV

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- SOSV (https://capitalatlas.ai/funds/sosv) — Series A
- Grupo Bimbo SAB de CV — Series A